Patents Examined by Jacintha M. Stall
  • Patent number: 5100776
    Abstract: The invention concerns an immunological detection process, with which triazines and structurally similar compounds and/or biologically equivalent compounds with similar bonding behavior are detected as belonging to one activity class, but with which on the other hand it is possible to identify the individual substances even in complicated mixtures.
    Type: Grant
    Filed: July 15, 1988
    Date of Patent: March 31, 1992
    Assignee: Dr. Pfeiffer Bioanalytik KG
    Inventors: Wolfgang Pfeiffer, Rudolf H. Dittel, Wolfgang Mies
  • Patent number: 5085984
    Abstract: Novel Fc receptors, denoted type VI, are disclosed as reacting with rat immunoglobulins with a reasonable affinity. These receptors, or the microorganisms which produce them, are useful in immunoassays.
    Type: Grant
    Filed: April 23, 1990
    Date of Patent: February 4, 1992
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Michael D. P. Boyle, Kathleen J. Reis
  • Patent number: 5081014
    Abstract: The method makes use of the action of the co-enzyme in the production of H.sub.2 O.sub.2 associated with the reaction of a hydroxylase with a decoupling agent in the presence of air or oxygen, the H.sub.2 O.sub.2 being subsequently determined by quantitative breaking of the C--F bond of a fluorinated compound in the presence of peroxidase, followed by electrometric titration of the resulting ions.
    Type: Grant
    Filed: September 19, 1990
    Date of Patent: January 14, 1992
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean Brochot, Iqbal Siddiqi
  • Patent number: 5079150
    Abstract: A new class of peroxidase substrates consists of o-diaminobenzenes having a substituent in the 4 position. The new substrates may be used in immunoassays in which a peroxidase is the label, or in assays for the peroxidase itself. Immunoassays using other enzyme labels which cause formation of hydrogen peroxide may be followed using the substrate of the invention by adding the substrate and a peroxidase to the assay fluid and detecting color formed as a result of oxidation of the substrate by the formed peroxide.
    Type: Grant
    Filed: November 17, 1988
    Date of Patent: January 7, 1992
    Assignee: Becton, Dickinson and Company
    Inventors: Daniel B. Wagner, Glen P. Vonk, Randy A. Hoke
  • Patent number: 5077220
    Abstract: A hybridoma cell line is provided which is capable of producing monoclonal antibodies which bind to a unique determinant site on the surface and/or in the cytoplasm of human breast carcinoma cells and carcinoma cells of other adenocarcinomas and on the surface of normal human breast epithelial cells. The cell line of the invention was developed by immunizing mice with a select group of immunogens and a conventional myeloma cell line for fusion with the murine splenocytes harvested.The monoclonal antibody is identified as the BrE2 monoclonal antibody. The antigen is characterized as a high molecular weight glycoprotein complex having a molecular exceeding 400,000 daltons. This monoclonal antibody is especially useful for diagnostic, prognostic and therapeutic applications in human breast cell carcinoma.
    Type: Grant
    Filed: August 26, 1988
    Date of Patent: December 31, 1991
    Assignee: John Muir Cancer & Aging Institute
    Inventors: Roberto L. Ceriani, Jerry A. Peterson
  • Patent number: 5075219
    Abstract: A hybridoma cell line is provided which is capable of producing a monoclonal antibody which binds to a unique determinant site on the surface and in the cytoplasm of human breast carcinoma cells and cells of other adenocarcinomas and does not bind selectively to the surface of normal breast epithelial cells except in instances of high concentration of the antibody in the testing fluid. The cell line of the invention was developed by immunizing mice with a select group of immunogens and a conventional myeloma cell line for fusion with the murine splenocytes harvested. The monoclonal antibody is identified as the BrE3 monoclonal antibody. The BrE3 monoclonal antibody binds to an antigen which is characterized as a high molecular weight glycoprotein complex having a molecular weight exceeding 400,000 daltons that is bound by a disulfide to a protein of 69,000 daltons.
    Type: Grant
    Filed: April 5, 1989
    Date of Patent: December 24, 1991
    Assignee: John Muir Cancer & Aging Institute
    Inventors: Roberto L. Ceriani, Jerry A. Peterson
  • Patent number: 5073484
    Abstract: A method and apparatus for the quantitative determination of an analyte in a liquid employs a liquid-permeable solid medium defining a liquid flow path. The medium includes a number of reaction-containing reaction zones spaced apart along the flow path and in which reaction occurs with the analyte or an analyte derivative (e.g., a labeled analyte) to result in the formation of a predetermined product. Detector means are employed to detect analyte, analyte derivatives, reactant or predetermined product in the reaction zones, the number of such zones in which such detection occurs indicating the amount of analyte in the liquid.
    Type: Grant
    Filed: February 23, 1983
    Date of Patent: December 17, 1991
    Assignee: Bio-Metric Systems, Inc.
    Inventors: Melvin J. Swanson, Patrick E. Guire
  • Patent number: 5073481
    Abstract: An assay to detect the presence of live hepatitis viruses in vitro. Bone marrow cells of leukemic cell line cells are exposed to a body fluid or biological preparation to be tested and the cells are placed in suspension. When using bone marrow cells, growth factors to the bone marrow stem cells are added. It has been determined that presence of a live hepatitis virus suppresses the growth of colonies of the stem cells. Therefore, if the number of colonies growing in the mixture are less than that number present in a culture of cells exposed to a sample that has been determined to contain no live virus, live hepatitis virus is present in the sample tested. The assay is particularly useful to determine the presence of live hepatitis B virus in a vaccine.
    Type: Grant
    Filed: November 30, 1989
    Date of Patent: December 17, 1991
    Assignee: Beth Israel Hospital Association
    Inventors: Jerome B. Zeldis, Robert P. Gale, Howard N. Steinberg
  • Patent number: 5068180
    Abstract: A substrate for .beta.-galactosidase having the general formula ##STR1## wherein X is halogen; Y is halogen, lower alkyl or hydrogen; W is lower alkyl or hydrogen; and Z is nitro.
    Type: Grant
    Filed: November 8, 1989
    Date of Patent: November 26, 1991
    Assignee: Technicon Instruments Corporation
    Inventors: Deng R. Hwang, Mary Ellen A. Scott
  • Patent number: 5066580
    Abstract: Novel xanthene dyes are disclosed which excite in the range of 450-650 nm and which will emit to the red of fluoroscein. These dyes may be coupled to tagging agents, such as monoclonal antibodies, and used to detect cells in a sample.
    Type: Grant
    Filed: February 16, 1990
    Date of Patent: November 19, 1991
    Assignee: Becton Dickinson and Company
    Inventor: Linda Lee
  • Patent number: 5043266
    Abstract: Light obtained from the reaction between a dihydrophthalazinedione such as luminol or isoluminol, an oxidant such as hydrogen peroxide, and a peroxidase enzyme is enhanced by addition of an ortho- or para- imidazolyl- or benzimidazolylphenol.The effect has particular application to diagnostic assays.
    Type: Grant
    Filed: May 31, 1988
    Date of Patent: August 27, 1991
    Assignee: National Research Development Corporation
    Inventors: Margaret H. Dewar, Robert S. Davidson
  • Patent number: 5035998
    Abstract: Reagents for the determination of hydrolase comprises compounds of the formula ##STR1## wherein Z is an organic or inorganic acid residue or a sugar residue, A is an organic or inorganic acid residue, and B is an organic acid residue. Each of R.sup.2 and R.sup.5, is hydrogen, halogen or lower alkyl. Each of R.sup.1, R.sup.3, R.sup.4 and R.sup.6, is hydrogen, halogen, cyano, lower alkyl, lower alkoxy, carboxyl, lower alkoxycarbonyl, carboxy lower alkyl or lower alkoxycarbonyl lower alkyl, or carboxamido groups optical substituted once or twice, or a radical of the formula--COO--(CH.sub.2 CH.sub.2 O).sub.n --R.sup.7in which R.sup.7 is hydrogen or lower alkyl and n is a number from 1 to 4. Additionally, R.sup.6 can be sulpho or nitro.
    Type: Grant
    Filed: November 13, 1989
    Date of Patent: July 30, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Herbert von der Eltz, Hans-Joachim Guder, Klaus Muhlegger
  • Patent number: 4994375
    Abstract: A stable human serum based control for the assay of Total LD and CK and their isoenzymes. This control may be lyophilized and reconstituted and still provide the same enzyme activity prior to lyophilization, for seven (7) days after reconstitution, if stored in the dark at or about 2.degree.0 to 8.degree. C. No thiol compounds other than the amount normally used to purify CK isoenzymes are found in this highly stable control.
    Type: Grant
    Filed: July 11, 1988
    Date of Patent: February 19, 1991
    Assignee: Baxter International Inc.
    Inventors: Alan Posner, Pedro Romero
  • Patent number: 4980280
    Abstract: The present invention relates to the synthesis of conjugated polyene sterol derivatives, the compounds obtained and to their use as fluorescent probes for cellular membranes. The fluorescent probes of the present invention resemble cholesterol both structurally and in amphipathic nature. The probes of the present invention have potential for use in determining cholesterol levels and cholesterol properties and cell membrane properties and can be applied to clinical assays and diagnoses involving cholesterol.
    Type: Grant
    Filed: May 31, 1989
    Date of Patent: December 25, 1990
    Assignee: University of Ottawa/Universite d'Ottawa
    Inventors: Peter Morand, Jacinta Drew, Arthur G. Szabo, Pierre R. Proulx